NCT05535517

Brief Summary

This validation study aims to develop a standardised investigator global assessment (IGA) score for keratosis pilaris and test the validity and reliability of the score through a one-day scoring exercise held at a private practice and compare it to a standard 0-4 IGA score specifically defined for keratosis pilaris.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 13, 2022

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

August 30, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

September 10, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2023

Completed
Last Updated

September 10, 2022

Status Verified

September 1, 2022

Enrollment Period

1 year

First QC Date

August 30, 2022

Last Update Submit

September 6, 2022

Conditions

Keywords

scoring systemIGA scoreseveritydisease assessmentKPevaluation

Outcome Measures

Primary Outcomes (1)

  • Keratosis Pilaris Area Index (KPAI)

    This study aims to develop and validate an IGA score for evaluating KP (KPAI) by determining the intra-rater and inter-rater reliability through testing the composite IGA score on patients and comparing it to a standard 0-4 IGA that will be defined specifically for KP.

    through study completion, an average of 1 year

Secondary Outcomes (2)

  • QOL questionnaires (DLQI/CDLQI)

    through study completion, an average of 1 year

  • QOL questionnaires (HADS)

    through study completion, an average of 1 year

Study Arms (4)

Group 1

KP Scoring Day Participants Participants who attend the one-day scoring session in August 2022.

Other: KPAIOther: KP-IGA

Group 2

KP Follow-up Scoring (September) Participants who attended the scoring day in August will be invited to attend a follow-up scoring session in September - October 2022. The purpose of this scoring session is to see how stable their condition is and take baseline photographs of their skin to monitor their condition. Four assessors will score the participants in 5-minute intervals with the proposed scoring system KPAI and the KP-IGA. Participants will be offered free samples of Cerave Salicylic Acid Smoothing Cleanser and Cream to try.

Other: CeraVe SA Smoothing CleanserOther: CeraVe SA Smoothing CreamOther: KPAIOther: KP-IGA

Group 3

KP Follow-up Scoring (November) Participants who attend the September scoring session will be invited to return for another rescoring in November - December 2022 to see if there is any improvement in their KP and if the score is responsive to change. Participants will be given free samples of Propaira 30% Urea exfoliating emollient and Propaira 20% Lactic acid exfoliating lotion to try.

Other: Propaira 20% Lactic Acid Exfoliating LotionOther: Propaira 30% Urea Exfoliating EmollientOther: KPAIOther: KP-IGA

Group 4

KP Follow-up Scoring (December) Participants who attend the November scoring session will be invited to return for another rescoring in December 2022 to monitor their progress, and see if there is any improvement in their KP and if the score is responsive to change.

Other: KPAIOther: KP-IGA

Interventions

The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.

Group 2

The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.

Group 2

For smoothing rough skin.

Group 3

30% Urea, 7% Glycerin to smoothen rough skin.

Group 3
KPAIOTHER

The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.

Also known as: Keratosis Pilaris Area Index
Group 1Group 2Group 3Group 4
KP-IGAOTHER

A standard 5-point IGA score (0-4) defined specifically for KP

Group 1Group 2Group 3Group 4

Eligibility Criteria

Age12 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients of the Principal Investigator's dermatology practice who have been diagnosed with keratosis pilaris.

You may qualify if:

  • All genders are allowed to participate
  • Age range: 12-80 years
  • Those with KP including subtypes of KP
  • Able to attend the one-day scoring session
  • Participants having read and understood the patient information and consent form and are willing to participate
  • Of mature mind and able to provide informed consent, in case of children (\< 18 years) then the guardian or caretaker can provide consent
  • Able to maintain compliance with required study related procedures including completing the QOL questionnaire's

You may not qualify if:

  • Participants who are unwilling or unable to attend the one-day scoring session
  • Those with other skin conditions overlapping the same area(s) as the KP

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Premier Specialists

Kogarah, New South Wales, 2222, Australia

RECRUITING

Related Publications (1)

  • Loh CC, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, Intong LR, Law MG, Murrell DF. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol. 2014 Jan;70(1):89-97.e1-13. doi: 10.1016/j.jaad.2013.09.041.

    PMID: 24355263BACKGROUND

MeSH Terms

Conditions

Burnett Schwartz Berberian syndrome

Study Officials

  • Dédée Murrell

    Premier Specialists

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Director of Premier Specialists

Study Record Dates

First Submitted

August 30, 2022

First Posted

September 10, 2022

Study Start

August 13, 2022

Primary Completion

August 30, 2023

Study Completion

August 30, 2023

Last Updated

September 10, 2022

Record last verified: 2022-09

Locations